Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future.
"For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call.
The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi.
Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million.
ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million.Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies.
ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added.
Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted.
ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said.The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal.
ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25.
"On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said.
The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
(You can now subscribe to our Economic Times WhatsApp channel)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
24 minutes ago
- Business Standard
Pvt players likely to have limited access to data from GatiShakti portal
Private sector may soon have limited access to the PM GatiShakti national masterplan (NMP) portal as the government has 'nearly finalised' rules around it, a senior government official said. The GatiShakti national masterplan is a digital platform that intends to reshape how India approaches infrastructure development. 'The rules are being framed in a way that private sector companies will not be allowed to download data from the national masterplan portal,' the official told Business Standard. The extent of data sharing with the private sector has been decided by the respective line ministries that have integrated their data with the national masterplan. All the ministries and departments have uploaded every minute data related to its social and economic projects on the portal. They can access this data and plan their own projects or social initiatives around it. As a result, it is reducing duplication of efforts, and easing movement of goods and people. For over two years, the department for promotion of industry and internal trade has held inter-ministerial meetings and has done extensive consultations with various government departments and ministries on the matter. The idea behind giving access of the national masterplan to private players has been to help them in execution of infrastructure projects, depending on the extent to which data is shared. In the Union Budget announcement in February, Finance Minister Nirmala Sitharaman had said that certain data and maps from the PM GatiShakti portal will be provided to the private sector -- a move which could help them optimise last-mile delivery services and develop infrastructure-based applications. Ahmedabad-based Bhaskaracharya National Institute for Space Applications and Geo-informatics (BISAG), under the administrative control of ministry of electronics and information technology (MeitY), is finalising the broader rules. BISAG's involvement is crucial since protocols for private users' access are sensitive considering security concerns, the official cited above said. At the moment, only state and central government ministries and departments can access the digital portal for detailed planning and implementation of infrastructure connectivity projects.
Mint
38 minutes ago
- Mint
Canadian dollar rebounds from one-week low after U.S. inflation report
Canadian dollar gains 0.2% against the greenback Touches its weakest since August 5 at 1.3806 Price of oil decreases 1% Bond yields rise across a steeper curve TORONTO, Aug 12 (Reuters) - The Canadian dollar recovered on Tuesday from an earlier one-week low against its U.S. counterpart after the release of U.S. inflation data that did not change expectations that the Federal Reserve would cut interest rates in September. The loonie was trading 0.2% higher at 1.3755 per U.S. dollar, or 72.70 U.S. cents, after touching its weakest intraday level since August 5 at 1.3806. "Given that the U.S. inflation print did not surprise to the upside it is likely we will see a reversal in USD-CAD near-term," said Sarah Ying, head of foreign exchange strategy at CIBC Capital Markets, adding that there is strong support for the pair in the 1.36 area. U.S. consumer prices increased moderately in July, though rising costs for services such as airline fares and tariff-sensitive goods like household furniture caused a measure of underlying inflation to post its largest gain in six months. Uncertain prospects for U.S. tariffs on Canadian goods and weaker-than-expected domestic employment data had pressured the loonie in recent days as the market considered pricing in more interest rate cuts from the Bank of Canada, Ying said. Minutes from the BoC's most recent policy decision, which resulted in the benchmark interest rate being left on hold at 2.75%, are due on Wednesday. Investors see a roughly 50% chance that the central bank will resume its easing campaign by October. Not all was positive for the Canadian currency, however. China announced preliminary anti-dumping duties on Canadian canola imports in a new escalation of a year-long trade dispute and the price of oil, one of Canada's major exports, was trading 1% lower at $63.31 a barrel. Canadian bond yields rose across a steeper curve. The 10-year was up 4.5 basis points at 3.441%, after earlier hitting its highest since August 1 at 3.466%. (Reporting by Fergal Smith, editing by Ed Osmond)
Time of India
an hour ago
- Time of India
UIDAI signs five-year R&D deal with Indian Statistical Institute on Aadhaar
Academy Empower your mind, elevate your skills The Unique Identification Authority of India (UIDAI) on Tuesday signed an umbrella agreement with the Indian Statistical Institute (ISI) for joint research and development (R&D) to further enhance the robustness, security and reliability of Aadhaar operations through data-driven innovations The collaborations will cover areas such as improvements in biometric liveness detection tools, matching algorithms and other priority areas, UIDAI said in a for five years, the agreement will cover areas such as fraud and anomaly detection, development of biometric liveness detection tools, identification of high-risk enrolment or update categories, improvements in biometric matching algorithms , and other priority areas.'Our collaboration with Indian Statistical Institute is a step towards building advanced, secure, and citizen-centric innovation ,' UIDAI CEO Bhuvnesh Kumar Kolkata-based ISI is a premier academic and research institution under the ministry of statistics and programme implementation (MoSPI). The 93-year-old institute is known for its expertise in the areas of statistics, mathematics, computer science, and data science, with a proven track record in high-impact research.
